The new immunosuppressive era.
Immunosuppression, although necessary to enable the graft to escape the consequence of immune surveillance carries some risks for the patients. There is an associated increase in neoplasm, opportunistic infections, and end-organ toxicity. In addition, even with excellent patient compliance, rejection (acute and chronic) remain a major limitation that contributes to the loss or decrease in the function of the allograft. New drugs have been added to the armamentarium of immunosuppressive agents to suppress allograft rejection and to rescue graft from cyclosporine-resistant. Most of the immunosuppressive agents in use today are direct at the T lymphocyte, non-specifically inhibiting T-cell activation and proliferation. The authors described here an update of these new immunosuppressive agents and new strategies used in solid organ transplantation.
Lo Monte
A I
AI
Jackson Memorial Hospital Department of Surgery, University of Miami School of Medicine, Florida, USA.
Ciancio
G
G
Burke
G
G
Roth
D
D
Miller
J
J
D016026:Bone Marrow Transplantation; D002678:Chimera; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007154:Immune System Diseases / Q000628:therapy*; D007108:Immune Tolerance; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016377:Organ Transplantation; D014181:Transplantation Immunology
D007166:Immunosuppressive Agents